ViiV Healthcare Cabenuva Meets Primary Endpoint in Phase IIIb CROWN Study of People With HIV Viremia
ViiV Healthcare Cabenuva (cabotegravir + rilpivirine) met the primary endpoint of the phase IIIb CROWN study, with superior six-month viral suppression versus standard oral ART in people with detectable HIV. The use is investigational and not approved.
